Scientists Find Hidden Alzheimer's Brain Buildups That May Appear Early

Scientists have uncovered a previously unknown type of brain plaque linked to Alzheimer’s disease, potentially altering the understanding of how the condition develops and offering new avenues for treatment. Researchers at the University of Minnesota identified what they describe as “mitochondrial plaques,” a novel feature of Alzheimer’s disease found in both preclinical models and human brain tissue. Their findings were published in Nature Neuroscience and suggest these plaques may appear earlier than the well-established beta-amyloid plaques, which have traditionally been viewed as a defining characteristic of the disease. The study highlights that mitochondrial plaques contain elevated levels of amyloid precursor protein, the molecular precursor to beta-amyloid. These plaques seem to form independently of traditional amyloid plaques and may arise during the earliest phases of Alzheimer’s. Unlike conventional plaques, which are located outside brain cells, mitochondrial plaques appear to directly impact neurons, making them a possible new target for therapeutic interventions. Paul Robbins, a professor at the University of Minnesota Medical School and associate director of the Masonic Institute on the Biology of Aging and Metabolism, described the discovery as identifying a previously unrecognized aspect of Alzheimer’s disease. He emphasized that understanding how these plaques form and their role in disease progression could lead to innovative strategies for slowing or preventing the illness. Xiuli Dan, a research assistant professor and lead author of the study, noted that the presence of mitochondrial plaques suggests Alzheimer’s-related changes might initiate earlier and via alternative biological mechanisms than previously believed. However, the research team cautioned that further investigation is necessary to confirm the full implications of this finding. Robbins explained that while the study indicates mitochondrial plaques may precede traditional amyloid plaques, it is currently unclear by how much. Present data show that these plaques can exist separately from amyloid plaques in the initial stages of the disease, with the two types often coexisting in later stages. Long-term studies using animal models and extensive analysis of human brain tissues across various disease stages are required to establish a definitive timeline. Laura Bojarskaite, a neuroscientist at the University of Oslo not affiliated with the research, suggested that if validated, the findings could significantly influence the scientific community’s perception of Alzheimer’s onset. She pointed out that the discovery might redirect attention towards internal neuronal processes rather than the external amyloid plaques that have dominated previous research. However, she stressed that establishing causality remains crucial. Bojarskaite raised the question of whether mitochondrial plaques actively drive neurodegeneration or merely indicate neurons already experiencing stress. This distinction would have major implications for future research directions and therapeutic approaches. The study also addresses a longstanding debate within Alzheimer’s research regarding the role of mitochondria in the disease process. Mitochondria, responsible for generating energy within cells, have been implicated in various neurological conditions due to their involvement in cellular metabolism and apoptosis. The identification of mitochondrial plaques adds another layer to this complex interplay, suggesting that disruptions in mitochondrial function may play a more prominent role in the disease’s progression than previously appreciated. As the research continues, scientists aim to explore the functional consequences of mitochondrial plaques and their interactions with other pathological features of Alzheimer’s. Future investigations will likely involve detailed molecular profiling, genetic analyses, and longitudinal studies to track the evolution of these plaques over time. The ultimate goal is to determine whether targeting mitochondrial plaques could offer new therapeutic opportunities for individuals at risk of developing Alzheimer’s disease.